Tocris Bioscience社 2012年6月新製品
New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules, peptides and antibodies being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can.
Cat.No. | Product Name | Activity |
4491 | DQP 1105 | Selective NR2C/NR2D receptor antagonist |
4545 | E 64d | Cathepsin inhibitor; interferes with autolysosomal digestion |
4472 | BAY 60-6583 | Potent A2B receptor agonist; cardioprotective |
4391 | Ro 51 | Potent P2X3, P2X2/3 antagonist |
4353 | TC-G 24 | Potent and selective GSK-3β inhibitor |
1478 | Proglumide sodium salt | Non-selective CCK antagonist; orally active |
4536 | Resiquimod | Toll-like receptor 7 (TLR7) agonist |
4532 | VUF 10166 | High affinity 5-HT3 receptor antagonist |
4531 | NCX 4040 | NO-donating aspirin; anti-inflammatory and antitumor |
4273 | LRRK2-IN-1 | Potent and selective LRRK2 inhibitor |
4252 | PF 4981517 | Selective CYP3A4 inhibitor |
4523 | DIDS | Chloride channel blocker; TRPV1 modulator; RAD51 recombinase inhibitor |
4462 | NS 3623 | hERG channel activator; antiarrhythmic |
4362 | PF 5081090 | Potent LpxC inhibitor |
4342 | UNC 0646 | Potent and selective G9a/GLP inhibitor |
2024 | PL 017 | Selective μ opioid receptor agonist |
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。